{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Herceptin+%28HER2-neu+positive+patients+only%29", "query": { "intervention": "Herceptin (HER2-neu positive patients only)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Herceptin+%28HER2-neu+positive+patients+only%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-12T20:03:34.502Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04538742", "title": "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2020-12-28", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 10, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Commack, New York + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04538742" }, { "nct_id": "NCT00875979", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab emtansine [Kadcyla] 3.0 mg/kg", "type": "DRUG" }, { "name": "Trastuzumab emtansine [Kadcyla] 3.6 mg/kg", "type": "DRUG" }, { "name": "Pertuzumab 420 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2009-05", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2013-12-24", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 10, "location_summary": "Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00875979" }, { "nct_id": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Mutant Non-small Cell Lung Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Gene Mutation", "HER2 Amplification" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2023-03-20", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 5, "location_summary": "Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650879" }, { "nct_id": "NCT05097599", "title": "StrataPATH™ (Precision Indications for Approved Therapies)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Advanced Solid Tumor" ], "interventions": [ { "name": "lorlatinib", "type": "DRUG" }, { "name": "encorafenib + binimetinib", "type": "DRUG" }, { "name": "talazoparib", "type": "DRUG" }, { "name": "sacituzumab govitecan", "type": "DRUG" }, { "name": "axitinib", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Strata Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2022-04-29", "completion_date": "2024-06-12", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 4, "location_summary": "St. Petersburg, Florida • Tallahassee, Florida • Kettering, Ohio + 1 more", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Kettering", "state": "Ohio" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05097599" }, { "nct_id": "NCT01501487", "title": "MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TAC chemotherapy", "type": "DRUG" }, { "name": "TC chemotherapy", "type": "DRUG" }, { "name": "Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy", "type": "DRUG" }, { "name": "TCH chemotherapy", "type": "DRUG" }, { "name": "T + trastuzumab followed by CEF + trastuzumab", "type": "DRUG" }, { "name": "Dose dense AC followed by T + trastuzumab", "type": "DRUG" }, { "name": "Dose dense AC followed by T + trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "PTH followed by dose dense AC of FEC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agendia", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 226, "start_date": "2011-10", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2018-06-28", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 9, "location_summary": "Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tarpon Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01501487" }, { "nct_id": "NCT00127933", "title": "XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "capecitabine [Xeloda]", "type": "DRUG" }, { "name": "Taxotere", "type": "DRUG" }, { "name": "Herceptin (HER2-neu positive patients only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 157, "start_date": "2005-08", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2011-08-10", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 38, "location_summary": "Los Angeles, California • Montebello, California • Palm Springs, California + 30 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Montebello", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127933" }, { "nct_id": "NCT00021255", "title": "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Herceptin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 3222, "start_date": "2001-04", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-11-15", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021255" }, { "nct_id": "NCT04395508", "title": "An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2022-07-05", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 12, "location_summary": "Beverly Hills, California • San Francisco, California • Stanford, California + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04395508" }, { "nct_id": "NCT02536339", "title": "A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-12-16", "completion_date": "2020-12-29", "has_results": true, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 16, "location_summary": "Tucson, Arizona • Duarte, California • Stanford, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02536339" }, { "nct_id": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1303/BNT323", "type": "BIOLOGICAL" }, { "name": "Pertuzumab Injection", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 796, "start_date": "2022-01-31", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-12T20:03:34.502Z", "location_count": 35, "location_summary": "Cerritos, California • Los Angeles, California • San Diego, California + 29 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05150691" } ] }